

Efgartigimod combined with glucocorticoids in the treatment of severe generalized myasthenia gravis: A single-center, retrospective cohort study

¹²³Shanshan Gu, ¹²Yongzhao Li, ¹Huimin Dong, ¹²Hongxia Yang, ¹Mei Ma, ¹Mengna Li, ¹²Congya Yan, ¹²Pei Jia, ¹²Yaxuan Wang, ¹²³Guoyan Qi*

1.Center of Treatment of Myasthenia Gravis, Shijiazhuang People's Hospital, Shijiazhuang, China,

2.Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China

3.Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China.

Corresponding author

E-mail: zzjwlsys@163.com

Supplementary Table 1: Subgroup analysis based on baseline QMG score. Patients were divided into "high baseline QMG" and "low baseline QMG" groups based on the median baseline QMG score. Within each subgroup, pairwise differences in QMG score changes between the treatment groups at Weeks 2 and 12 were compared.

Subgroup	Variable	Group		Statistic	p	p.adj
Low baseline QMG	QMG_2w_delta	A	B	-2.187	0.029	0.172
	QMG_2w_delta	A	C	-0.886	0.376	1
	QMG_2w_delta	A	D	-2.056	0.04	0.239
	QMG_2w_delta	B	C	1.28	0.2	1
	QMG_2w_delta	B	D	0.895	0.371	1
	QMG_2w_delta	C	D	-0.671	0.502	1
	QMG_12W_delta	A	B	1.098	0.272	1
	QMG_12W_delta	A	C	-0.053	0.957	1
	QMG_12W_delta	A	D	-0.603	0.546	1
	QMG_12W_delta	B	C	-1.002	0.316	1
	QMG_12W_delta	B	D	-1.464	0.143	0.859
	QMG_12W_delta	C	D	-0.401	0.689	1
High baseline QMG	QMG_2w_delta	A	B	-2.304	0.021	0.127
	QMG_2w_delta	A	C	-0.142	0.887	1
	QMG_2w_delta	A	D	-1.211	0.226	1
	QMG_2w_delta	B	C	2.028	0.043	0.255
	QMG_2w_delta	B	D	1.334	0.182	1
	QMG_2w_delta	C	D	-0.953	0.34	1
	QMG_12W_delta	A	B	-0.471	0.638	1
	QMG_12W_delta	A	C	0.397	0.692	1
	QMG_12W_delta	A	D	-1.707	0.088	0.527
	QMG_12W_delta	B	C	0.786	0.432	1
	QMG_12W_delta	B	D	-0.96	0.337	1
	QMG_12W_delta	C	D	-1.957	0.05	0.302

Abbreviations: QMG, Quantitative Myasthenia Gravis; 2W, 2 week; 12W, 12 week. P, P-value; p.adj, adjusted P-value.